IRIS
MAZZASCHI, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.847
AS - Asia 4.536
EU - Europa 3.133
SA - Sud America 647
AF - Africa 272
Continente sconosciuto - Info sul continente non disponibili 171
OC - Oceania 11
Totale 14.617
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.582
SG - Singapore 1.551
IT - Italia 1.197
CN - Cina 881
VN - Vietnam 807
BR - Brasile 478
HK - Hong Kong 364
BD - Bangladesh 355
IE - Irlanda 329
SE - Svezia 314
DE - Germania 292
FR - Francia 218
ZA - Sudafrica 170
GB - Regno Unito 146
NL - Olanda 144
IN - India 140
CA - Canada 121
RU - Federazione Russa 108
AT - Austria 84
FI - Finlandia 76
AR - Argentina 61
MX - Messico 51
TR - Turchia 51
KR - Corea 45
IQ - Iraq 42
JP - Giappone 38
ID - Indonesia 36
ES - Italia 35
PH - Filippine 35
EC - Ecuador 33
CZ - Repubblica Ceca 29
PK - Pakistan 29
PL - Polonia 29
BE - Belgio 28
CI - Costa d'Avorio 28
CO - Colombia 26
UA - Ucraina 24
UZ - Uzbekistan 23
TH - Thailandia 21
VE - Venezuela 20
CR - Costa Rica 18
MA - Marocco 17
HN - Honduras 14
LT - Lituania 14
GT - Guatemala 13
IR - Iran 13
NI - Nicaragua 13
TW - Taiwan 13
IL - Israele 12
SA - Arabia Saudita 12
EG - Egitto 11
MY - Malesia 11
TN - Tunisia 11
AU - Australia 10
CL - Cile 10
JO - Giordania 10
LU - Lussemburgo 10
EE - Estonia 9
KE - Kenya 9
KZ - Kazakistan 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
PY - Paraguay 7
SC - Seychelles 7
AZ - Azerbaigian 6
JM - Giamaica 6
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
CH - Svizzera 4
DK - Danimarca 4
KH - Cambogia 4
NG - Nigeria 4
OM - Oman 4
PS - Palestinian Territory 4
BA - Bosnia-Erzegovina 3
BB - Barbados 3
GP - Guadalupe 3
GR - Grecia 3
HU - Ungheria 3
LB - Libano 3
MD - Moldavia 3
MK - Macedonia 3
PA - Panama 3
PE - Perù 3
PR - Porto Rico 3
RS - Serbia 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AL - Albania 2
AO - Angola 2
BS - Bahamas 2
BY - Bielorussia 2
CG - Congo 2
CW - ???statistics.table.value.countryCode.CW??? 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
GY - Guiana 2
KG - Kirghizistan 2
Totale 14.419
Salva come PNG Salva come JPEG
Città #
Singapore 898
Ashburn 876
San Jose 672
Dallas 514
Santa Clara 395
Hong Kong 342
Dublin 325
Chandler 313
Ho Chi Minh City 247
Council Bluffs 236
Parma 213
Boardman 199
Beijing 196
Hanoi 174
Johannesburg 157
Los Angeles 152
New York 148
Munich 131
Ann Arbor 126
Shanghai 104
Milan 103
Bologna 97
Lauterbourg 95
Hefei 94
Vienna 64
Rome 59
Buffalo 58
Chicago 49
São Paulo 48
Bremen 41
Da Nang 41
Helsinki 40
Columbus 38
Moscow 38
Princeton 38
Frankfurt am Main 37
Modena 37
Montreal 36
Atlanta 33
Dearborn 33
Marseille 33
Seoul 32
Nuremberg 30
Toronto 30
Haiphong 29
North Bergen 29
Abidjan 28
Phoenix 28
Denver 27
London 27
Nanjing 27
Tokyo 27
Brussels 26
Turku 26
Verona 25
Orem 23
Boston 22
Chennai 22
Houston 22
The Dalles 22
West Jordan 22
Seattle 21
Reggio Emilia 20
Warsaw 20
Amsterdam 19
Bengaluru 19
Brooklyn 19
Des Moines 18
Mexico City 18
Guangzhou 17
Tashkent 17
Baghdad 16
Brno 15
Jakarta 15
Pune 15
Rio Saliceto 15
Wilmington 15
Jinan 14
Naples 14
Poplar 14
Rio de Janeiro 14
Lahore 13
Redondo Beach 13
Stockholm 13
Tianjin 13
Venice 13
Belo Horizonte 12
Biên Hòa 12
Brescia 12
Florence 12
Guatemala City 12
Guayaquil 12
Izmir 12
Managua 12
San José 12
Brasília 11
Fremont 11
Hải Dương 11
Quito 11
Amman 10
Totale 8.616
Salva come PNG Salva come JPEG
Nome #
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 260
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 231
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 229
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 222
227P Sexual dimorphism in immune profile of early and advanced NSCLC 215
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 214
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 212
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 210
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 204
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 202
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 201
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 201
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 198
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 197
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 193
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 192
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 190
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 190
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 189
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 188
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 187
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 180
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 178
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 176
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 174
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 174
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 174
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 171
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 168
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 167
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 166
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 166
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 165
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 163
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 162
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 161
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 156
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 154
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 151
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 150
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 149
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 145
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 145
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 144
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 143
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 142
Deciphering the different patterns of acquired resistance in immunotherapy treated NSCLC patients through an integrated clinical and blood immuneinflammatory profiling 140
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy 138
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 137
A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study 134
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 133
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 133
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non–Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study 133
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 132
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 130
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 129
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy 129
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 129
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 128
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations 127
9P Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model 127
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status 127
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 126
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 126
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 124
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 124
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient 122
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 120
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 119
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 118
Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer 117
Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology 116
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 115
Drug-drug interactions (DDIs) in elderly patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib within the multicenter prospective trial ZEBRA/Meet-URO 9 114
Burnout and Oncology: an irreparable paradigm or a manageable condition? Prevention strategies to reduce Burnout in Oncology Health Care Professionals 113
Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study 113
Evaluation of PBRM1, PD-L1, CD31, and CD4/CD8 ratio as a predictive signature of response to VEGFR-TKI–based therapy in patients with metastatic renal cell carcinoma (mRCC) with IMDC intermediate prognosis: Results from the APAChE-I Study 111
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 110
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 107
The distinct prognostic impact of circulating lipid profile according to neutrophil to lymphocyte ratio in patients with advanced solid tumors treated with immune check point inhibitors. 104
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 104
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 101
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 100
The radiological appearances of lung cancer treated with immunotherapy: a review 99
Abscopal effect as part of treatment of oligometastatic head and neck cancer: A case report 95
The role of c-met as a biomarker and player in innate and acquired resistance in non-small-cell lung cancer: Two new mutations warrant further studies 92
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 92
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups 86
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 86
Cytoreductive nephrectomy in the era of targeted- And immuno- therapy for metastatic renal cell carcinoma: An elusive issue? A systematic review of the literature 85
Evaluation of PBRM1, PD-L1, CD31 and CD4/CD8 ratio as predictive biomarkers of response to VEGFR-TKI-based therapy in metastatic renal cell carcinoma (mRCC) patients with IMDC intermediate prognosis: Results from the APAChE-I study 83
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 81
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 78
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 78
Immune checkpoint inhibitors in hepatocellular cancer patient with congenital haemophilia A 77
What Is the Real Impact of Concomitant Antibiotics or Proton Pump Inhibitors on Efficacy of Atezolizumab-Based Regimens in Patients With NSCLC? 76
Integration of tissue and circulating parameters identifies a favorable immune profile in NSCLC patients treated with nivolumab 76
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis 76
Exploring genetic and immune underpinnings of the sexual dimorphism in tumor response to immune checkpoints inhibitors: A narrative review 71
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma 71
Totale 14.261
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.274
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.274
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022212 0 0 0 0 5 12 60 10 6 10 21 88
2022/20231.306 121 129 72 109 143 143 38 73 391 7 56 24
2023/2024876 33 60 28 36 110 157 97 36 62 80 49 128
2024/20252.804 92 177 226 197 261 244 183 132 253 271 237 531
2025/20267.113 582 512 983 604 796 374 630 322 930 557 456 367
2026/20271.618 259 371 352 570 66 0 0 0 0 0 0 0
Totale 14.617